Crystal Structure of Human E-Cadherin-EC1EC2 in Complex with a Peptidomimetic Competitive Inhibitor of Cadherin Homophilic Interaction.

Cadherins are transmembrane cell adhesion proteins whose aberrant expression often correlates with cancer development and proliferation. We report the crystal structure of an E-cadherin extracellular fragment in complex with a peptidomimetic compound that was previously shown to partially inhibit cadherin homophilic adhesion. The structure reveals an unexpected binding mode and allows the identification of a druggable cadherin interface, thus paving the way to a future structure-guided design of cell adhesion inhibitors against cadherin-expressing solid tumors.

[1]  Peter D. Kwong,et al.  Structural basis of cell-cell adhesion by cadherins , 1995, Nature.

[2]  M. Ikura,et al.  Structural basis of calcium-induced E-cadherin rigidification and dimerization , 1996, Nature.

[3]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[4]  A. Vagin,et al.  MOLREP: an Automated Program for Molecular Replacement , 1997 .

[5]  O. Pertz,et al.  A new crystal structure, Ca2+ dependence and mutational analysis reveal molecular details of E‐cadherin homoassociation , 1999, The EMBO journal.

[6]  B. L. Sibanda,et al.  Protein-Protein Interactions in Receptor Activation and Intracellular Signalling , 2000, Biological chemistry.

[7]  O. Blaschuk,et al.  A Novel Family of Cyclic Peptide Antagonists Suggests That N-cadherin Specificity Is Determined by Amino Acids That Flank the HAV Motif* , 2000, The Journal of Biological Chemistry.

[8]  Gareth Williams,et al.  Dimeric Versions of Two Short N-cadherin Binding Motifs (HAVDI and INPISG) Function as N-cadherin Agonists* , 2002, The Journal of Biological Chemistry.

[9]  T. Boggon,et al.  C-Cadherin Ectodomain Structure and Implications for Cell Adhesion Mechanisms , 2002, Science.

[10]  S. Grzesiek,et al.  Proteolytic E‐cadherin activation followed by solution NMR and X‐ray crystallography , 2004, The EMBO journal.

[11]  R. Hazan,et al.  Cadherin Switch in Tumor Progression , 2004, Annals of the New York Academy of Sciences.

[12]  B. Gumbiner,et al.  Regulation of cadherin-mediated adhesion in morphogenesis , 2005, Nature Reviews Molecular Cell Biology.

[13]  Fabiana Bahna,et al.  Type II Cadherin Ectodomain Structures: Implications for Classical Cadherin Specificity , 2006, Cell.

[14]  E. Parisini,et al.  The crystal structure of human E-cadherin domains 1 and 2, and comparison with other cadherins in the context of adhesion mechanism. , 2007, Journal of molecular biology.

[15]  M. Takeichi,et al.  Cadherin-11 in Synovial Lining Formation and Pathology in Arthritis , 2007, Science.

[16]  Yusuke Nakamura,et al.  Identification of a Novel Tumor-Associated Antigen, Cadherin 3/P-Cadherin, as a Possible Target for Immunotherapy of Pancreatic, Gastric, and Colorectal Cancers , 2008, Clinical Cancer Research.

[17]  B. Honig,et al.  Dynamic properties of a type II cadherin adhesive domain: implications for the mechanism of strand-swapping of classical cadherins. , 2008, Structure.

[18]  Gema Moreno-Bueno,et al.  Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. , 2008, Cancer research.

[19]  O. Blaschuk,et al.  Cadherins as novel targets for anti-cancer therapy. , 2009, European journal of pharmacology.

[20]  G. Berx,et al.  Involvement of members of the cadherin superfamily in cancer. , 2009, Cold Spring Harbor perspectives in biology.

[21]  S. M. Burden-Gulley,et al.  Novel peptide mimetic small molecules of the HAV motif in N-cadherin inhibit N-cadherin-mediated neurite outgrowth and cell adhesion , 2009, Peptides.

[22]  A. Mancuso,et al.  Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  A. Tomassetti,et al.  E-cadherin directly contributes to PI3K/AKT activation by engaging the PI3K-p85 regulatory subunit to adherens junctions of ovarian carcinoma cells , 2009, Oncogene.

[24]  B. Honig,et al.  T-cadherin structures reveal a novel adhesive binding mechanism , 2010, Nature Structural &Molecular Biology.

[25]  B. Honig,et al.  Two-step adhesive binding by classical cadherins , 2010, Nature Structural &Molecular Biology.

[26]  Randy J. Read,et al.  Acta Crystallographica Section D Biological , 2003 .

[27]  Y. Bang,et al.  Down-regulation of P-cadherin with PF-03732010 inhibits cell migration and tumor growth in gastric cancer , 2012, Investigational New Drugs.

[28]  Randy J. Read,et al.  Overview of the CCP4 suite and current developments , 2011, Acta crystallographica. Section D, Biological crystallography.

[29]  O. Blaschuk.  Discovery and development of N-cadherin antagonists , 2012, Cell and Tissue Research.

[30]  Fabiana Bahna,et al.  Molecular design principles underlying β-strand swapping in the adhesive dimerization of cadherins , 2011, Nature Structural &Molecular Biology.

[31]  S. Rakshit,et al.  Ideal, catch, and slip bonds in cadherin adhesion , 2012, Proceedings of the National Academy of Sciences.

[32]  D. Leckband,et al.  Cadherin recognition and adhesion. , 2012, Current opinion in cell biology.

[33]  Maria Sofia Fernandes,et al.  Epithelial E- and P-cadherins: role and clinical significance in cancer. , 2012, Biochimica et biophysica acta.

[34]  D. Jonker,et al.  Phase I clinical trial of Exherin (ADH-1) in patients with advanced solid tumors. , 2013, Current clinical pharmacology.

[35]  B. Honig,et al.  Mechanism of E-cadherin dimerization probed by NMR relaxation dispersion , 2013, Proceedings of the National Academy of Sciences.

[36]  T. Kodama,et al.  Identification and characterization of the X-dimer of human P-cadherin: implications for homophilic cell adhesion. , 2014, Biochemistry.

[37]  S. Byers,et al.  Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies , 2013, Oncotarget.

[38]  E. Parisini,et al.  The X-ray structure of human P-cadherin EC1-EC2 in a closed conformation provides insight into the type I cadherin dimerization pathway. , 2015, Acta crystallographica. Section F, Structural biology communications.

[39]  M. Civera,et al.  Computational design of novel peptidomimetic inhibitors of cadherin homophilic interactions. , 2015, Organic & biomolecular chemistry.

[40]  Tom L. Blundell,et al.  Flexibility and small pockets at protein–protein interfaces: New insights into druggability , 2015, Progress in biophysics and molecular biology.

[41]  G. Rákhely,et al.  Reversible Opening of Intercellular Junctions of Intestinal Epithelial and Brain Endothelial Cells With Tight Junction Modulator Peptides. , 2016, Journal of pharmaceutical sciences.

[42]  Donald W. Miller,et al.  Comparison of Linear and Cyclic His-Ala-Val Peptides in Modulating the Blood-Brain Barrier Permeability: Impact on Delivery of Molecules to the Brain. , 2016, Journal of pharmaceutical sciences.